Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...
TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty
TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, ...
Milestone Pharmaceuticals price target lowered to $10 from $25 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...
Milestone Pharmaceuticals (NASDAQ:MIST) Rating Lowered to “Hold” at TD Securities
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) was downgraded by analysts at TD Securities from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday,BayStreet ...
Milestone Pharmaceuticals (MIST) was downgraded to a Hold Rating at TD Cowen
Milestone Pharmaceuticals (MIST – Research Report) received a Hold rating and price target from TD Cowen analyst Ritu Baral today. The ...
American Association of Individual Investors6d
Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Down 61.33%
Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 61.33%, which has investors questioning if this is right time to buy.
Milestone Pharmaceuticals’ (MIST) “Buy” Rating Reiterated at HC Wainwright
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They ...
Reuters6d
Milestone Pharmaceuticals Inc
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a ...
Investing3d
Milestone Pharmaceuticals stock rating cut to hold by TD Cowen
On Tuesday, TD Cowen analysts lowered the stock rating for Milestone Pharmaceuticals (NASDAQ:MIST) from Buy to Hold. The change comes following the company’s receipt of a Complete Response Letter (CRL ...
Stocktwits on MSN6d
Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive
Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...
Investing3d
Milestone Pharmaceuticals stock rating cut to hold by TD Cowen
On Tuesday, TD Cowen analysts lowered the stock rating for Milestone Pharmaceuticals (NASDAQ:MIST) from Buy to Hold. The change comes following the company’s receipt of a Complete Response ...
Emcure subsidiary Tillomed Laboratories to acquire UK based Manx Healthcare and its subsidiaries
Tillomed Laboratories, a subsidiary of Emcure Pharmaceuticals, has entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare and its subsidiaries, Manx Pharma and Manx Generics ...